FTC loses Impax pay-for-delay case
A Federal Trade Commission administrative law judge has found that the procompetitive benefits of a reverse-payment settlement between drugmakers Endo and Impax outweighed the anticompetitive harm.
Subscribe to Global Competition Review
Subscribe and start reading now
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10